174 related articles for article (PubMed ID: 12939814)
1. [Correlation between tumor necrosis factor alpha and matrix metalloproteinases levels in serum of patients with rheumatic arthritis].
Klimiuk PA; Sierakowski S; Chwiećko J
Pol Merkur Lekarski; 2003 May; 14(83):410-2. PubMed ID: 12939814
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
3. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
[TBL] [Abstract][Full Text] [Related]
6. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
7. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
[TBL] [Abstract][Full Text] [Related]
8. [Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis].
Klimiuk PA; Sierakowski S; Fiedorczyk M; Chwiećko J
Przegl Lek; 2004; 61(2):86-9. PubMed ID: 15230147
[TBL] [Abstract][Full Text] [Related]
9. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
Bellometti S; Richelmi P; Tassoni T; Bertè F
Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
[TBL] [Abstract][Full Text] [Related]
10. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
[TBL] [Abstract][Full Text] [Related]
11. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
Klimiuk PA; Sierakowski S; Chwiećko J
Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
[TBL] [Abstract][Full Text] [Related]
12. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
13. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
14. Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer.
Braundmeier AG; Nowak RA
Am J Reprod Immunol; 2006 Sep; 56(3):201-14. PubMed ID: 16911716
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.
Anand SP; Selvaraj P
Clin Immunol; 2009 Oct; 133(1):126-31. PubMed ID: 19615945
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
Tchetverikov I; Kraan MC; van El B; Hanemaaijer R; DeGroot J; Huizinga TW
Ann Rheum Dis; 2008 Jan; 67(1):128-30. PubMed ID: 17875551
[TBL] [Abstract][Full Text] [Related]
18. Pro-inflammatory cytokine, matrix metalloproteinases and TIMP-1 are involved in wound healing after mastectomy in invasive breast cancer patients.
Loo WT; Sasano H; Chow LW
Biomed Pharmacother; 2007 Oct; 61(9):548-52. PubMed ID: 17904786
[TBL] [Abstract][Full Text] [Related]
19. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone.
Hulejová H; Baresová V; Klézl Z; Polanská M; Adam M; Senolt L
Cytokine; 2007 Jun; 38(3):151-6. PubMed ID: 17689092
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
